Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NivoCUP-2 expanded access program of nivolumab for cancer of unknown primary
jRCT2051200146Active, not recruiting
- Start
- May 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Open-label, single-arm trial of nivolumab in cancer of unknown primary (CUP). Primary endpoint: Safety and feasibility of nivolumab for cancer of unknown primary. Started May 2021; status: active, not recruiting.
02
Drugs
03
Conditions
cancer of unknown primary (CUP)
Beyond the preview
Go deeper on jRCT2051200146.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051200146.